141 related articles for article (PubMed ID: 38096467)
21. Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients.
Césaire M; Rambeau A; Clatot F; Johnson A; Heutte N; Thariat J
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2453-2461. PubMed ID: 36564669
[TBL] [Abstract][Full Text] [Related]
22. Machine Learning-Guided Adjuvant Treatment of Head and Neck Cancer.
Howard FM; Kochanny S; Koshy M; Spiotto M; Pearson AT
JAMA Netw Open; 2020 Nov; 3(11):e2025881. PubMed ID: 33211108
[TBL] [Abstract][Full Text] [Related]
23. A novel nomogram and risk classification system for predicting overall survival in head and neck squamous cell cancer with distant metastasis at initial diagnosis.
Zhu RQ; Zhang YM; Luo XY; Shen WY; Zhu HY
Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1467-1478. PubMed ID: 36316576
[TBL] [Abstract][Full Text] [Related]
24. Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes.
Xu H; Lin M; Hu Y; Zhang L; Li Q; Zhu J; Wang S; Xi M
Oncologist; 2021 Mar; 26(3):e425-e434. PubMed ID: 32960471
[TBL] [Abstract][Full Text] [Related]
25. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
[TBL] [Abstract][Full Text] [Related]
26. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors.
Pike LRG; Bang A; Mahal BA; Taylor A; Krishnan M; Spektor A; Cagney DN; Aizer AA; Alexander BM; Rahma O; Balboni T; Ott PA; Hodi FS; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):142-151. PubMed ID: 30227198
[TBL] [Abstract][Full Text] [Related]
27. A machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer.
Xu Z; Yang L; Yu H; Guo L
Front Oncol; 2022; 12():905222. PubMed ID: 36185193
[TBL] [Abstract][Full Text] [Related]
28. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?
Chadha AS; Liu G; Chen HC; Das P; Minsky BD; Mahmood U; Delclos ME; Suh Y; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH; Wang X; Thames H; Krishnan S
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):323-332. PubMed ID: 28068240
[TBL] [Abstract][Full Text] [Related]
29. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas.
Ho WJ; Yarchoan M; Hopkins A; Mehra R; Grossman S; Kang H
J Immunother Cancer; 2018 Aug; 6(1):84. PubMed ID: 30170629
[TBL] [Abstract][Full Text] [Related]
30. High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta-analysis.
Yang L; Huang Y; Zhou L; Dai Y; Hu G
Head Neck; 2019 May; 41(5):1525-1535. PubMed ID: 30597654
[TBL] [Abstract][Full Text] [Related]
31. An ion-channel-gene-based prediction model for head and neck squamous cell carcinoma: Prognostic assessment and treatment guidance.
Han Y; Shi Y; Chen B; Wang J; Liu Y; Sheng S; Fu Z; Shen C; Wang X; Yin S; Li H
Front Immunol; 2022; 13():961695. PubMed ID: 36389709
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment hematological parameters as predictors of tumor granulocyte-colony-stimulating factor expression in patients of head-and-neck squamous cell carcinoma.
Waghmare CM; Pawar HJ; Deshpande NS; Karle RR; Angarkar NN; Thakur PK
J Cancer Res Ther; 2023; 19(3):657-663. PubMed ID: 37470590
[TBL] [Abstract][Full Text] [Related]
33. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
34. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
Davuluri R; Jiang W; Fang P; Xu C; Komaki R; Gomez DR; Welsh J; Cox JD; Crane CH; Hsu CC; Lin SH
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):128-135. PubMed ID: 28816138
[TBL] [Abstract][Full Text] [Related]
35. Influence of comorbidity on therapeutic decision making and impact on outcomes in patients with head and neck squamous cell cancers: Results from a prospective cohort study.
Agarwal J; Adulkar D; Swain M; Chakraborty S; Gupta T; Budrukkar A; Ghosh-Laskar S; Murthy V
Head Neck; 2019 Mar; 41(3):765-773. PubMed ID: 30552822
[TBL] [Abstract][Full Text] [Related]
36. Which model is better in predicting the survival of laryngeal squamous cell carcinoma?: Comparison of the random survival forest based on machine learning algorithms to Cox regression: analyses based on SEER database.
Sun H; Wu S; Li S; Jiang X
Medicine (Baltimore); 2023 Mar; 102(10):e33144. PubMed ID: 36897699
[TBL] [Abstract][Full Text] [Related]
37. A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
Teknos TN; Grecula J; Agrawal A; Old MO; Ozer E; Carrau R; Kang S; Rocco J; Blakaj D; Diavolitsis V; Kumar B; Kumar P; Pan Q; Palettas M; Wei L; Baiocchi R; Savvides P
Invest New Drugs; 2019 Aug; 37(4):702-710. PubMed ID: 30569244
[TBL] [Abstract][Full Text] [Related]
38. Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.
Hernando-Calvo A; Mirallas O; Marmolejo D; Saavedra O; Vieito M; Assaf Pastrana JD; Aguilar S; Bescós C; Lorente J; Giralt J; Benavente S; Temprana-Salvador J; Alberola M; Dienstmann R; Garralda E; Felip E; Villacampa G; Brana I
Oral Oncol; 2023 May; 140():106364. PubMed ID: 36989964
[TBL] [Abstract][Full Text] [Related]
39. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma.
Mehrazin R; Uzzo RG; Kutikov A; Ruth K; Tomaszewski JJ; Dulaimi E; Ginzburg S; Abbosh PH; Ito T; Corcoran AT; Chen DY; Smaldone MC; Al-Saleem T
Urol Oncol; 2015 Sep; 33(9):388.e19-25. PubMed ID: 25027688
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
